In this enlightening session, Dr. Jill Carnahan dives deep into the cutting-edge world of probiotics and the game-changing “Un-Hunger Hormone” with none other than biotech pioneer, Colleen Cutcliffe.
Join us as we explore the revolutionary GLP-1 Probiotic, a groundbreaking innovation that promises to boost GLP-1 production and transform metabolic health. Colleen Cutcliffe, CEO and co-founder of Pendulum, shares her expertise on how this unique probiotic can effectively manage hunger, improve gut health, and support overall wellness.
💖 20% Discount: Go to https://pendulumlife.com/DRJILL to get 20% off of all membership first orders applied at checkout.
Key Points
- The science behind GLP-1 and its crucial role in regulating appetite and blood sugar levels.
- How the GLP-1 Probiotic is different from traditional probiotics and what makes it a powerful tool for enhancing health.
- The story behind Pendulum and how it’s leading the charge in biotech innovations for a healthier future.
- Practical tips and insights from Colleen Cutcliffe on incorporating the GLP-1 Probiotic into your daily routine.
Don't miss out on Dr. Jill Carnahan's insightful questions and Colleen Cutcliffe's expert answers that demystify the incredible benefits of enhancing GLP-1 production through probiotics.
💖 20% Discount: Go to https://pendulumlife.com/DRJILL to get 20% off of all membership first orders applied at checkout.
Key Points
🚀 Boost your body's natural GLP-1 production with Pendulum's groundbreaking probiotic!
👩🏻⚕️ Led by biotech pioneer Colleen Cutcliffe Pendulum is revolutionizing health with our multi-strain GLP-1 Probiotic. 🧬💪
🧬Harness your body's power to produce more GLP-1 naturally. It's science-backed innovation at its finest!
💪Ready to transform your health? Visit pendulumlife.com/drjill for an exclusive 20% off your first order!
👍🏼 GLP-1 Probiotic helps you take control of cravings by helping to produce more of this key natural hormone that helps to curb your appetite, reduce cravings, and helps you feel full faster.
✅ Helps maintain a healthy weight
GLP-1 is the “un-hunger” hormone that sends a message to your brain that you’re full; a natural hormone produced in your gut in response to eating.
💖 20% Discount: Go to https://pendulumlife.com/DRJILL to get 20% off of all membership first orders applied at checkout.
Our Guest – Colleen Cutcliffe
Colleen’s Bio: Colleen Cutcliffe is the CEO and Co-Founder of Pendulum. She has over 25 years of experience leading and managing biology teams in academia, pharmaceuticals and biotechnology. Prior to starting Pendulum, Colleen was the Senior Manager of Biology at Pacific Biosciences and a Scientist at Elan Pharmaceuticals. Colleen received her Ph.D. in Biochemistry and Molecular Biology from Johns Hopkins University and her B.A. in Biochemistry from Wellesley College.
Dr. Jill Carnahan, MD
Dr. Jill Carnahan is Your Functional Medicine Expert® dually board certified in Family Medicine for ten years and in Integrative Holistic Medicine since 2015. She is the Medical Director of Flatiron Functional Medicine, a widely sought-after practice with a broad range of clinical services including functional medical protocols, nutritional consultations, chiropractic therapy, naturopathic medicine, acupuncture, and massage therapy.
As a survivor of breast cancer, Crohn’s disease, and toxic mold illness she brings a unique perspective to treating patients in the midst of complex and chronic illness. Her clinic specializes in searching for the underlying triggers that contribute to illness through cutting-edge lab testing and tailoring the intervention to specific needs.
A popular inspirational speaker and prolific writer, she shares her knowledge of hope, health, and healing live on stage and through newsletters, articles, books, and social media posts! People relate to Dr. Jill’s science-backed opinions delivered with authenticity, love and humor. She is known for inspiring her audience to thrive even in the midst of difficulties.
Featured in Shape Magazine, Parade, Forbes, MindBodyGreen, First for Women, Townsend Newsletter, and The Huffington Post as well as seen on NBC News and Health segments with Joan Lunden, Dr. Jill is a media must-have. Her YouTube channel and podcast features live interviews with the healthcare world’s most respected names.
The Podcast
The Video
The Transcript
224: Resiliency Radio with Dr. Jill: GLP-1 Probiotic & the _Un-Hunger Hormone with Colleen Cutcliffe
Dr. Jill 00:00
Welcome to Resiliency Radio, your go-to podcast for the most cutting-edge insights in integrative and functional medicine. I'm your host, Dr. Jill, and in each episode, we dive into the heart of healing and personal transformation. Join us as we interview renowned thought leaders, medical experts, and just all around really cool people.
Dr. Jill 00:18
Today, we have a really special episode with one of my favorite partners. We're going to deep dive into probiotics and why you need to know about the latest technology that's available. My guest is Colleen Cutcliffe, the CEO and co-founder of Pendulum. She has over 25 years of experience leading and managing biology teams in academia, pharmaceuticals, and biotechnology. Prior to starting Pendulum, Colleen was the senior manager of biology at Pacific Biosciences and a scientist at Elan Pharmaceuticals. Colleen received her PhD in biochemistry and molecular biology from Johns Hopkins University and her bachelor of arts in biochemistry from Wellesley College. Welcome, Colleen. It's good to talk to you again.
Colleen Cutcliffe 01:00
Thank you so much. Thanks for having me.
Dr. Jill 01:02
You're welcome. I always get so excited about the things that really work in clinical practice, and today we're going to do a deep dive onto why I'm so passionate about Pendulum and about your products and all the science behind them. I always love to start with stories. So tell us, how did you get from bioscience, bioengineering, biotechnology, all the realm in that world, into making probiotics and creating a new development?
Colleen Cutcliffe 01:27
I think one of the really interesting things that not a lot of people know is that all the probiotics that are on the shelves right now are representing a very small fraction of the strains that are in our gut microbiome. The technological advancements in the biotech industry around DNA sequencing have enabled us to unlock: What are all the different bacteria, viruses, and fungi that are in us and on us and play an important role in our health? And how can we start to map them? And how can we start to approach this like a systems biology problem with all the data that we actually need in order to develop next-generation probiotics that can really help us in a wide variety of health and disease indications?
Colleen Cutcliffe 02:10
I got super excited from a technology standpoint, which is to say, oh my gosh, we have the ability now to generate all this data, to create these maps, and to start to investigate, “What are the other 99% of those microbes doing and how can they help us benefit our health?” and to bring those to people in a meaningful way that can help them change their health and improve their health in ways that people can measure and really feel that are different than what's on the market today. To me, that was a really exciting opportunity driven by technology that enables us to make headway in science and medicine to then make changes in people's lives. And it's been an exciting decade-plus working in the field.
Dr. Jill 02:49
I love that so much. And from my perspective as a clinician, I want to do what works. I really just care about the bottom line and seeing the patients lives change, the metabolic dysfunction reversed. So I got really excited. And I'll tell you my little backstory: I've been teaching in most of the faculties on functional medicine training for doctors for 20 years, and I have been teaching the gut modules for a long time. So I always talk about probiotics. And like you said, what's really interesting [is that] if you really look at 10 strains, 20 strains—the classical stuff that's been out there—the evidence isn't that strong for what we've been typically using.
Dr. Jill 03:26
That's why this is exciting because, from my perspective, I knew for decades that Akkermansia was a keystone strain and that it was so correlated with diversity, even by itself, just as a marker. And as I saw that. Well before I knew about Pendulum, I would tell the doctors: “If anyone ever comes up with a probiotic that has Akkermansia, they are going to be doing really well because this is so critical.” So for me, it was like seeing that vision and then seeing it come to life with what you guys have done. And maybe before we jump into some of the newest, coolest stuff you're doing with the GLP probiotic, let's talk just a little bit about: Why has Akkermansia been so long coming to the forefront? Why is it so difficult to get this into a probiotic?
Colleen Cutcliffe 04:08
I think there are a couple of things about Akkermansia that make it so powerful but also make it so hard to make into a probiotic and bring it to life. The first thing is that when we talk about the gut microbiome and where Akkermansia is residing, we're really talking about the distal colon. Think about when you eat food: It goes to your stomach, it goes to the entire GI tract, and on the end of that—the distal colon part of that—that's where all the action is happening in the microbiome. It turns out that in that area where all these exciting next-generation probiotics are residing, there's no oxygen. There's a lot of oxygen in the environment around us, so if you want to be able to manufacture that strain, you have to figure out: “How do I create an end-to-end closed system that keeps oxygen out in order to be able to grow that strain?” That's problem number one.
Colleen Cutcliffe 04:54
Problem number two is that Akkermansia literally lives in the mucin layer and consumes mucin in order to survive and to grow. Mucin is a beef byproduct. If you want to get Akkermansia to grow outside of that environment and you want to be able to grow it in a vegetable-based media, which are some of the requirements in the U.S., you have to figure out: What can I feed it that's not what it's used to eating and have it still grow and have all the activities it's supposed to have? So, oxygen-free. How do you get it from not needing to consume a beef byproduct?
Colleen Cutcliffe 05:28
And then the third thing is, after you're able to manufacture it outside the body in this artificial system, how do you then get it to get back to the distal colon and the microbiome, open up, reactivate, do all of its work, and provide benefits? So you've got a problem of: How do I get it out of that system and grow it? Then how do I get it back into the system? And then how do I get it to be functional again?
Colleen Cutcliffe 05:51
When you take all those challenges together that haven't really been solved by anybody else, it feels very daunting. And luckily for us, we didn't realize any of that when we jumped into this. We were like, “Akkermansia—let's grow it!”
Dr. Jill 06:02
It was probably good that you were so not aware of the difficulties because who knows if it would have happened.
Colleen Cutcliffe 06:08
Exactly. It's like having kids. It's best to not know what's going to happen here, because if you knew, you'd be like, “Oh my gosh, this is terrible!” So I think the not knowing is what enabled us to really jump in, and it's the knowing that probably kept all the existing manufacturers from jumping into it. So that's the one-two punch of why I think Akkermansia has taken so long to get to the market.
Dr. Jill 06:30
Yeah. And many clinicians like myself have been so excited. I want to jump into GLP-1 because I know that's what people want to hear about today. But before we do, your flagship product—the Glucose Control—tell us just a little bit about that because that's clinically what I've been using and having incredible success with A1Cs and stuff. Do you want to tell us just a little bit about the combination, why it's so powerful, and what you're seeing clinically in the studies?
Colleen Cutcliffe 06:56
Yes. And actually, Glucose Control is a product that I take every day as well.
Dr. Jill 06:59
Me too. Me too.
Colleen Cutcliffe 07:02
Yes. We can talk a little bit about that—those of us who are taking it so-called “off-label.” Essentially, when we started this endeavor, we believed that the gut microbiome is tied to metabolism and that there is a way to change the microbiome in ways that can impact your metabolism. We approached this the way you would a pharmaceutical drug, where we said, “What does it mean to have bad metabolism?” So you look at metabolic syndrome and you go all the way to this part of the spectrum, which is type 2 diabetes.
Colleen Cutcliffe 07:33
When we think about metabolic syndrome, there are healthy, obese, pre-diabetes, and type 2 diabetes. Then we said, “If we can really help the people who are on the sick end here and have been diagnosed with type 2 diabetes, then that might be able to translate down the line through this whole spectrum.” We started with type 2 diabetes, and we created our own data set but also looked at data that was being generated globally through a bunch of different amazing academic groups. What they showed was that healthy people had a ton of certain functions in their microbiome that were low or entirely missing in people who had type 2 diabetes.
Colleen Cutcliffe 08:10
You can even do a twin study, which is what we did, where you look at twins that are discordant. You have a healthy twin, and you have a twin with diabetes or obesity, and you say: “What's the difference between these two people? Because they're genetically the same, what is it about them that's making one person have to struggle with a disease and the other person healthy?” What we found is that in their microbiome, there was this same pattern where the healthy twin had a ton of certain functions, and the twin that was sick was missing these functions. What those functions boil down to when you uncover it and you look at those strains is something that has been extremely well-known to medicine for a long, long time. Namely, it is the production of the short-chain fatty acid butyrate. These people who were sick didn't have the strains that could make butyrate.
Colleen Cutcliffe 08:53
One of the important things about butyrate is that it stimulates GLP-1. GLP-1, we'll talk about, but that has become well-known in the world because of Ozempic and Wegovy trying to mimic our body's natural GLP-1. But all of these are ways in which your microbiome stimulates GLP-1 production. As soon as we saw that, we said, “Oh my gosh, this is a huge unlock!” We already know GLP-1 is really important for diabetes. And now we've unlocked the parts of the microbiome that increase GLP-1. If you could give those microbes back to people—the theory is you're missing it, that's why you're not making GLP-1 right—and if we could give these back to you, you would be able to increase your GLP-1 levels.
Colleen Cutcliffe 09:33
The way that that should play out for patients is you should see your A1C go down, and you should see your blood glucose spikes go down. The clinical trial that we ran was, after eight years of development, a double-blinded placebo-controlled randomized trial where we showed that people who were on this formulation as opposed to placebo had a lowering of their A1C by 0.6 and a lowering of their blood glucose spikes by 33%.
Colleen Cutcliffe 09:59
It was an amazing discovery to showcase that you could change a person's microbiome and that that could show up for people in lowering A1C and blood glucose spikes. And it's been really awesome to continue to work on the science and get to hear stories from practitioners like you who are seeing it play out in real life too.
Dr. Jill 10:21
Yeah, I can't tell you the number. I bet 80% of my patients are on one of your probiotics or another because they're so effective and so well tolerated. And that's an interesting thing too: I treat the sickest of the sick—the mast cell patients, the severe gut dysbiosis, the Crohn's, the colitis, the metabolic dysfunction, the mold toxicity—and because those patients are extra sensitive, I have not had a lot of issues with sensitivity or anything.
Dr. Jill 10:44
Now, as you talked, one thing I know from our previous interview [is that] you had eight years of research, and then you had this theory that you were testing. But what you didn't tell was the nail-biting of waiting for those results because you didn't know going into that—all the money that was spent on the investments to the company—the outcome. Now we look back and are like, “Oh, wow, this is amazing!” Of course, right? But going into that, you didn't know what that study was going to show, right? How did that feel when it finally came out that it was so positive?
Colleen Cutcliffe 11:11
Oh, it was so great! And this is one of those things where you do so much work upfront and you have so many theories about what's going to work. And then it really is a nail-biter because you start the clinical trial and everything is double-blinded. You're blind. And you just want to sit there and pray every night that you have a positive outcome because now it really is out of your hands. It's almost like you spend all this time making a resume, polishing it, thinking about: “What is that person going to want to see, that hiring manager, and how do I make myself presented in the best way possible?” And then you submit it, and then you just wait, like, “Am I going to get an interview?” That's really what it feels like. And it feels like it's out of your control. You've done the best you can. So to get that interview or to get those clinical outcomes was amazing because we set out to really help people improve their health, and now we had created a tool that could really help people.
Colleen Cutcliffe 12:04
And it was also a funny moment too because I remember being like, “Oh my gosh, look at this clinical trial outcome.” Like, “We're done. Life's over now. Put it out in the world and we're good to go.” The mission of our company has never been, “Oh, go create great products.” The mission of the company is to help millions of people improve their lives through the products we create. And that—helping millions of people—is actually non-trivial. So I'm really grateful to you for hosting podcasts like this where you can bring information to the world because now it's like, “How do you help people know that this exists and how it's going to help them?” That's really the end goal, and we have not gotten there yet.
Dr. Jill 12:42
Gosh, no. And I am right there with you. You're the only product company that's been funded by Mayo Clinic, and you've got Halle Berry as a spokesperson. And I'm so proud of you guys and so happy to support you because, like I said, all that matters for me is what works in clinical practice. And when I find something that I use and that works, I can't not talk about it. And that's why I'm here, because it just flows right out of me. I'll be on the street being like, “Hey, have you heard about Pendulum?”—because it's really powerful. So I love, love, love that.
Dr. Jill 13:12
You mentioned GLP-1. You kind of described what it is. Obviously, people are so familiar with that term and with the drugs that are out there. But what I want to clarify and then let you talk a little bit about this—because this is the newest probiotic that you guys have developed—is the fact that our body makes GLP-1. So many people think about drugs and are like, “Oh, well, that's a drug.” Well, yes, but… And it is an agonist, so it's different from your natural production. But this is an endogenous peptide that we produce in our gut, and it allows for a decrease in leptin resistance and all kinds of things. Do you want to talk just a little bit about the endogenous production? What is this molecule? And then we can talk about the probiotic and how that has an effect on our own production.
Colleen Cutcliffe 13:51
Sure. If we nerd out a little bit on biology here, effectively what happens is that when you eat a meal, you have these trillions of microbes in your microbiome that are metabolizing that food. And within that factory of trillions of microbes, there's a department, and that department is comprised of a few different of these microbes. And what they do is, when they metabolize that food, they stimulate the production of GLP-1. That's their job. When they stimulate the production of GLP-1, that gets released into your bloodstream and your GLP-1 levels go up. And GLP-1 is a really powerful small molecule because it does two key things. One is that it stimulates your insulin response so that you can metabolize the sugars that you just ate. And two, it tells your brain: We just ate; we're full; we don't need to eat anymore.
Colleen Cutcliffe 14:35
The really powerful thing about this small molecule is that you're metabolizing sugars, and you're giving your brain the signal that we don't need to eat anymore. After these GLP-1 levels go up in your bloodstream, after a while, they'll go back down. And then you'll get hungry again, and it'll be time to eat again. You're supposed to be on this natural cycle of GLP-1 hormone going up and down as you eat, helping you manage your food cravings and helping you metabolize your sugars.
Colleen Cutcliffe 15:03
What the drugs do is they basically said, “Oh my gosh, that's super powerful. What if I could all the time be telling my brain I'm full? What if I could all the time be metabolizing my sugars? Let's make a chemical drug that looks like the GLP-1 hormone. Let's inject it directly in the bloodstream, and then it'll just be at high levels all the time instead of this cycle.” And that's what the drugs do. You inject them; they keep your GLP-1 levels really high all the time. So you get these very immediate impacts—your food noise is gone, and you're metabolizing your sugars.
Colleen Cutcliffe 15:35
I think that one of the things that we're going to learn is: What are the longer-term repercussions of being on this very high level that doesn't follow your body's natural cycle? And I think about it like if I was speaking to you through a megaphone. You would definitely be able to hear me more clearly, like loud and clear. But if I kept speaking to you through a megaphone, eventually you're going to go deaf and then it's not going to have the same effect. The same thing happens in our body, where these beta cells, which are really important for helping us metabolize our sugars, can become deaf to signaling. It's one of the reasons why if you've been on insulin for a long time, sometimes it can start to lose its efficacy because you literally are doing this loudspeaker effect where your cells become deaf to the signal. I think we just have to be careful about how we think about when to use a loudspeaker and when not to use a loudspeaker in different situations. And that's probably the biggest learning we'll have over the next 5 or 10 years around the drugs.
Colleen Cutcliffe 16:31
But your body can naturally produce GLP-1. So if you want to go to that mode, you can increase these strains in your gut microbiome, which will stimulate your body's natural GLP-1. You'll get back into the cycle that you're supposed to have. And not only will you get back into the cycle, but you'll be able to do it in a sustainable way. So if you have the right foods that you're eating that can sustain these strains and help keep them colonized, you could ideally go off the strains, and you've taught your body to fish. You'll still be able to make this GLP-1. And that's also from the drugs, where you're not teaching your body how to make that. So when you go off the drugs, you have this big rebound. You don't have that problem when you're teaching your body how to make it on its own.
Dr. Jill 17:15
What a great, clear explanation for those listening who don't already know by now. It's so much on the news and everything and podcasting that I can't imagine someone doesn't understand. But one thing just clinically—I'm not making recommendations or giving medical advice—in my practice, what I've really come to like to use is microdosing of the medications to stimulate and shift a patient's metabolism who wants to lose weight. And then I'll put in something like your GLP-1 probiotic to support their natural production and do the diet, the lifestyle, and the supplements. So we do the whole thing. And what I find is I get way better results with way less side effects. It can be used for people who are slightly overweight versus severe obesity.
Dr. Jill 17:56
And again, this is off-label. I'm not making medical recommendations, but in my clinical practice, I see this work really well. And it is my favorite way to use them because it's just like a little bit of a nudge, and then we get their own body doing the work. And people can come off of these things and do really, really well.
So, let's talk about [how] your probiotic is very deliberately created with certain strains because you can have food for the Akkermansia. Tell us about that mix and why that mix is so important in the GLP-1.
Colleen Cutcliffe 18:24
Sure. There are only two strains that have ever been published to be able to show that they can directly stimulate GLP-1 production. One of them is Akkermansia muciniphila. The other one is Clostridium butyricum. This formulation that we made has both of those in it. And we added a third strain, which works in tandem with those other two strains called Bifidobacterium infantis. This formulation is very specifically designed to increase your body's GLP-1 levels.
Colleen Cutcliffe 18:53
One of the things that I want to point out here too is that people are thinking about—if you've tried Ozempic or things like that versus this natural thing—that this is not a magic weight loss pill. I want to be really clear about that because we do have people who go try it and they're like, “I didn't lose 10 pounds in the first week.” And you're not going to. And you're not going to lose 10 pounds in the two weeks either. When you're teaching your body how to do this naturally, it's going to take a second, so you have to invest in it. And I also think it's really important to move out of having weight loss be the focal point and have good nutrition and food cravings be the focal point.
Colleen Cutcliffe 19:33
The idea here is that we all have these undesired food cravings. There's a food cravings inventory, which is a test that tells you: What are your food cravings around sugars, around carbs, around fast foods, around high-fat foods? Those are the four primary types of food cravings that we have. What we know is that when people are on this probiotic, you get a reduction in all of those food cravings. After being on this for six weeks, 91% of people had a reduction in those food cravings. The reason that that should be the metric that you're focused on is because that's how you get sustainable change. Now imagine you don't crave all these sugars. You can start to make really good food choices and you get on the better hamster wheel. You get off the bad hamster wheel onto the better hamster wheel, which is you're making better food choices. That's going to improve your gut health. That's going to improve all of your energy levels and, in a sustainable way, help you to live a healthier life.
Colleen Cutcliffe 20:25
I think that the mistake that you can make is that if you're just solely focused on weight, you can do things that are really detrimental to your body in order to lose that weight when, in fact, if you're really focused on better nutrition and better choices and reduced food cravings, that's going to help you in the long run to maintain a healthy weight. So I just wanted to give the caveat: Not a weight loss pill.
Dr. Jill 20:48
No, I completely agree. It works so well with a functional approach because often that dysbiosis—overgrowth in the small bowel of bacteria or fungus—is part of the driving factor of the cravings. I've even seen it reduce alcohol cravings and other things. So what happens is that it gives them a tool to adhere to a new lifestyle plan that they already usually want to do. It's just that sometimes our willpower is a little weak. I feel like it's just the superpower. It helps with the willpower. And then, like I said, for patients who are getting off medications, it can be helpful as a transition as well.
Dr. Jill 21:22
I'm so excited that you developed that and really, really wanted to focus on that today. Anything new on the horizon that you see maybe coming out in the future, new technology, or anything else that you guys have as far as things that might be available for us clinicians?
Colleen Cutcliffe 21:41
Yes.
Dr. Jill 21:42
[inaudible] to talk about, right?
Colleen Cutcliffe 21:45
I'm trying to think about: How do I share this? We are definitely, as you know, always very excited about: How can we continue to create evidence-based formulations that are going to help people? We've been very focused on metabolism because I think that, first of all, all of us think about our metabolism. So maybe selfishly I'm making products that I want to take. And the gut microbiome—most people have thought about probiotics as helping with GI distress. So we've really, I think, focused on metabolism. And that's one thing that really sets us apart from all the other things that are out there. We're the first and the only probiotics company that has a probiotic for type 2 diabetes that can lower your A1C. So when we think about “How do we expand beyond that?” it really does start to get into thinking about not just the probiotics but also the prebiotics. So that's the teaser that I'll give you.
Dr. Jill 22:34
Perfect. That's all we need. I'll be watching because I love the stuff you guys are doing.
Thank you for your visionary approach and for you being such a part of seeing that this could be a possibility because it really is already changing the lives of so many clinicians and the thousands of patients that each of us see. And we're so excited about that and about the new things that are coming up.
Dr. Jill 22:55
Guys, if you're watching this and you want to check it out yourself, we do have a discount code for you. You can go to PendulumLife.com\drjill, and you can get 20% off your first membership order. We'll have that in the notes. If you're driving or listening to this on your headphones while you're running, don't worry about getting the code. It's just DRJILL. But you can get that 20% off if you're listening and want to check it out for yourself. I would recommend it. And Colleen, I'd love your advice on this, but if you are wanting to give it a try—I'm on the Glucose Control; I probably will be on it for life—90 days is a great way to start. If I want to check my numbers, if you want to talk to your doctor, I think a 90-day trial… Is that what the length of the trial was—90 days initially? Or, what do you recommend?
Colleen Cutcliffe 23:34
Yes, that's exactly right. The length of the trial was 90 days. And I 100% agree with you. Giving yourself a 90-day challenge and seeing if you can experience a difference is the best way to trial this. And I'll just say too, as we think about medications versus this product, what to expect. We all know that when you go on any drug, what you can expect is that there's going to be all these negative side effects that you have to worry about. One of the advantages to improving your gut health is that it flips everything on its head. What we hear from people and what people experience are side effects that are things that you're not expecting because you've actually improved your gut health.
Colleen Cutcliffe 24:11
For example, it's not just about lowering your blood glucose levels, it's not just about lowering your A1C, but it's also about when you are able to manage your blood glucose spikes and troughs, you'll have reduced food cravings. You'll have better-sustained energy. You have better, stronger workouts. You don't get that post-lunch food slump that we all get. Two o'clock is a terrible time to have a meeting because everybody's exhausted. You don't get that. And for a lot of people, they also have better sleep. And we're doing studies around that. What you'll experience is heightened levels of energy, more sustainable energy, and more of a flattening out and not being on a roller coaster throughout the day and the reduced food craving. So I hope everyone gives it a 90-day shot. And see if you experience all those hard benefits as well as soft benefits.
Dr. Jill 24:54
Gosh, thanks for explaining that. And I think that the key there too is that a lot of people don't know that their hidden fluctuations in energy are blood sugar-related. So this is a cool thing to prove that that is connected and have more sustained energy. Colleen, as always, it's such a joy talking to you. Thank you for taking the time to come on today.
Colleen Cutcliffe 25:14
Thanks so much for having me.
Dr. Jill 25:15
You're welcome. And everybody who's listening, thanks again for joining us for another episode of Resiliency Radio. As you know, you can find transcripts and all of our episodes at JillCarnahan.com or anywhere you listen to podcasts. And join us next week for a new episode.
Share: